Dimensional Fund Advisors LP Has $1.06 Billion Holdings in Gilead Sciences, Inc. $GILD

Dimensional Fund Advisors LP cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,557,768 shares of the biopharmaceutical company’s stock after selling 566,769 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Gilead Sciences were worth $1,061,087,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Brighton Jones LLC raised its holdings in shares of Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after buying an additional 2,450 shares in the last quarter. Bison Wealth LLC bought a new stake in Gilead Sciences during the 4th quarter worth approximately $215,000. Sivia Capital Partners LLC increased its holdings in Gilead Sciences by 16.8% in the second quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after purchasing an additional 602 shares during the period. GHP Investment Advisors Inc. increased its stake in shares of Gilead Sciences by 1.0% in the second quarter. GHP Investment Advisors Inc. now owns 12,513 shares of the biopharmaceutical company’s stock valued at $1,387,000 after buying an additional 124 shares during the period. Finally, TIAA Trust National Association raised its holdings in Gilead Sciences by 0.4% during the 2nd quarter. TIAA Trust National Association now owns 24,560 shares of the biopharmaceutical company’s stock worth $2,723,000 after purchasing an additional 109 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on GILD shares. The Goldman Sachs Group boosted their price objective on Gilead Sciences from $110.00 to $115.00 and gave the company a “neutral” rating in a research note on Thursday, January 8th. Cantor Fitzgerald upped their price objective on shares of Gilead Sciences from $135.00 to $155.00 and gave the stock an “overweight” rating in a report on Wednesday, February 11th. TD Cowen raised their target price on Gilead Sciences from $145.00 to $160.00 and gave the company a “buy” rating in a report on Wednesday, February 11th. Mizuho raised their price target on shares of Gilead Sciences from $140.00 to $170.00 and gave the company an “outperform” rating in a research report on Wednesday, February 18th. Finally, JPMorgan Chase & Co. boosted their price objective on Gilead Sciences from $150.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. Twenty-three equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and a consensus price target of $156.72.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $147.83 on Wednesday. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55. The stock has a market cap of $183.52 billion, a PE ratio of 21.84, a price-to-earnings-growth ratio of 1.97 and a beta of 0.37. Gilead Sciences, Inc. has a fifty-two week low of $93.37 and a fifty-two week high of $157.29. The stock has a fifty day moving average of $137.07 and a 200-day moving average of $125.27.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The firm had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The company’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same period in the prior year, the firm posted $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be paid a $0.82 dividend. The ex-dividend date is Friday, March 13th. This represents a $3.28 dividend on an annualized basis and a yield of 2.2%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio is currently 46.68%.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead agreed to acquire Arcellx for about $7.8 billion in cash, materially expanding its oncology and cell‑therapy footprint and signalling strategic diversification away from sole reliance on the HIV franchise — a potential long‑term revenue and valuation kicker if clinical programs progress. Gilead Sciences Arcellx Deal Deepens Oncology Bet And Tests HIV Reliance
• Positive Sentiment: Recent quarterly results beat on both EPS and revenue and management gave FY‑2026 EPS guidance (8.45–8.85), supporting the earnings story and dividend coverage. This remains a fundamental positive underpin. MarketBeat GILD Coverage (earnings, guidance)
• Neutral Sentiment: Analyst commentary and momentum stories (e.g., Zacks) are supporting investor interest but are sentiment drivers rather than new fundamentals. Why Gilead Sciences (GILD) is a Top Momentum Stock
• Neutral Sentiment: Gilead presented at the TD Cowen healthcare conference (transcript available) — useful for details on pipeline and strategy but unlikely to immediately move the stock without new data. TD Cowen Presentation Transcript
• Neutral Sentiment: Short‑interest data in recent reports is effectively meaningless (reported as 0 shares/0 days) and is not a driver of today’s move.
• Neutral Sentiment: Gilead Foundation’s $12M award for community HIV prevention is positive PR but immaterial to near‑term financials. Gilead Foundation Awards $12 Million
• Negative Sentiment: CEO Daniel O’Day sold 10,000 shares (reported average ~$144.79) — part of a series of insider sales this quarter. While not large relative to total holdings, insider selling can amplify short‑term selling pressure or raise investor caution. SEC Form 4 — Insider Sale

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $154.44, for a total transaction of $4,324,320.00. Following the completion of the sale, the insider directly owned 120,288 shares in the company, valued at $18,577,278.72. The trade was a 18.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total transaction of $617,500.00. Following the sale, the director directly owned 8,920 shares of the company’s stock, valued at $1,101,620. This represents a 35.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 309,280 shares of company stock valued at $43,935,470. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.